Sucampo must live with Takeda as Amitiza arbitration fails to go its way
This article was originally published in Scrip
Sucampo Pharmaceuticals' loss of an arbitration decision relating to a key partnership for its main commercial product Amitiza (lubiprostone) means that, like it or not, it will have to continue working with existing North American licensee Takeda.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.